Gemcitabine Plus Carboplatin in Patients with Advanced Hepatocellular Carcinoma: Results of a Phase II Study

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left">Response rate</td><td align="center">No. (%)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">Partial response</td><td align="center">9 (23%)</td></tr><tr><td align="left">Stable disease</td><td align="center">18 (46%)</td></tr><tr><td align="left">Progressive disease</td><td align="center">13 (31%)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

International Scholarly Research Notices

tab2

Table 2

Table 2: Gemcitabine Plus Carboplatin in Patients with Advanced Hepatocellular Carcinoma: Results of a Phase II Study 